Emerging Pharmacotherapies for Diabetic Macular Edema

Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME...

Descripción completa

Detalles Bibliográficos
Autores principales: Javey, Golnaz, Schwartz, Stephen G., Flynn, Harry W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299388/
https://www.ncbi.nlm.nih.gov/pubmed/22474425
http://dx.doi.org/10.1155/2012/548732
Descripción
Sumario:Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

Ejemplares similares